新华社成都6月12日电 中药材基因解码协同发力、精准医学转化研究平台共建、AI+药物研发合作…… 正在成都举行的第二届"一带一路"科技交流大会上，中医药领域的科技合作成为与会人士热议的话题。 "这次大会将给大家带来更多合作机会，推动更多创新医疗科技成果惠及共建'一带一路'国家，为全球 健康事业贡献力量。"坦桑尼亚教育、科学与技术部部长阿道夫·姆肯达说。（记者 董小红） "中医药在印尼非常受欢迎。中国在中医药现代化上有很多新的科技成果，我们期盼更多中医师到印尼 交流，把这些科技成果带到印尼。"6月11日，在"一带一路"传统医学合作暨中医药现代化国际科技大会 上，来自印尼的中医药专家林秋波说。 中国工程院院士张伯礼当天在《守正创新，推动中医药高质量发展》的主旨报告中说，为了提高中药生 产的效率，中国研制了AI机器人，可以降低成本，提升成效。他介绍，研究人员通过AI进行文本的挖 掘，包括专利、文献的分析，对依赖经验的传统中医药处方进行优化，对新药研发具有重要意义。 会上，四川大学华西医院副院长吴泓面向共建"一带一路"国家正式发布了8个国际合作项目，包含肝脏 微创技术、胸腔镜手术、超声前沿技术等领域，推动了国际医学创 ...

Core Viewpoint - BGI Genomics has officially established a strategic partnership with the Shenzhen Data Exchange, launching its first comprehensive tumor database, marking a significant step towards transforming into a data-driven intelligent medical ecosystem [2][9]. Group 1: Strategic Cooperation - The partnership aims to deepen collaboration in key areas such as data product innovation, industry data standard construction, data compliance and security, financialization of data assets, and data space development [2]. - BGI Genomics is transitioning from a traditional genetic testing service provider to a data-driven intelligent medical ecosystem, leveraging its proprietary platform and technological advantages to build a comprehensive database reflecting the genetic characteristics of the Chinese population [9][11]. - The cooperation is seen as a critical move to construct an autonomous data ecosystem and implement the national strategy of "data elements × healthcare" [9]. Group 2: Industry Context - The global precision medicine market is experiencing rapid growth, and China's data element market reform is making significant breakthroughs, with Shenzhen leading the way by establishing a data exchange and regulatory framework for compliant data circulation [4][5]. - The collaboration is positioned as a key starting point for the value development of genetic data, aiming to explore innovative paths for compliant development and application of genetic data [11]. - The initiative addresses critical industry challenges such as data security, privacy protection, and complex regulatory compliance, providing a systematic framework to enhance overall governance in the sector [13]. Group 3: Product Launch - BGI Genomics has launched a gene data product, the comprehensive tumor database, which integrates authoritative global genetic variation and treatment data while focusing on clinical guidelines and practice data unique to China [13]. - This product aims to provide high-value data services for precision medicine research and alleviate challenges associated with reliance on international databases [13].

Summary of GeneDx Conference Call Company Overview - GeneDx was established 25 years ago at the National Institutes of Health, focusing on diagnosing difficult cases, particularly in rare diseases [4][5] - The company has built the largest rare disease data asset in the U.S., with over 800,000 exomes and genomes and more than 6,100,000 phenotypic data points [5][6] Strategic Initiatives - GeneDx aims to reduce the diagnostic odyssey, which currently takes about five years, to weeks or even hours [5][6] - The company is focusing on increasing utilization in pediatric outpatient settings and NICUs [6] Differentiation and Market Position - GeneDx's tests are differentiated by their extensive data assets, which include a highly representative database and a robust phenotypic data set [7][8] - Approximately 60% of the time, both parents are tested, enhancing the accuracy of diagnoses [7] - The company claims an 80% market share among expert geneticists, with significant growth potential in pediatric neurology and NICU settings [14][16] Market Penetration - In pediatric neurology, GeneDx has only penetrated about 14% of the patient population, indicating substantial growth opportunities [16] - In NICUs, fewer than 5% of babies currently receive genetic testing, despite studies showing that 60% would benefit from it [19][22] - GeneDx aims to increase its NICU testing to approximately 225,000 tests annually, targeting a quarter million children by 2026-2027 [24] Product Development and Testing - GeneDx has launched a two-day ultra-rapid turnaround time for genome testing, which is expected to enhance market uptake [25][26] - The company is expanding its testing indications to include conditions like cerebral palsy and hearing loss, focusing on the best clinical outcomes [29][30] Financial Performance and Cost Management - GeneDx has achieved profitability and aims for continued profitable growth, focusing on areas with sufficient reimbursement [17][18] - The company has reduced denial rates from 65% to less than 50% for pediatric neurologists, improving reimbursement rates and gross margins [48][49] - Current gross margins for exome and genome testing are around 80%, with ongoing efforts to reduce costs further through automation and technology [54][56] Future Growth and Market Strategy - GeneDx plans to expand into adult genetic testing as reimbursement pathways develop, aiming for early diagnosis across all age groups [62][63] - The company is also exploring monetization of its extensive data set for biopharma, aiming to contribute to drug discovery and clinical trial development [64][66] Conclusion - GeneDx is positioned as a leader in genetic testing for rare diseases, with a strong focus on data-driven diagnostics and expanding market opportunities in pediatric and adult settings. The company is committed to improving patient outcomes through faster and more accurate testing while maintaining a focus on profitability and cost management.

本次研讨会以"精准医学"为主线，国内外生殖医学领域权威专家、临床医生、科研人员聚焦辅助生殖技 术（ART）的精准化、个体化发展展开讨论，共话辅助生殖技术精准化发展。研讨会上，国内外顶尖专 家也带来了精彩的前沿技术分享。 新京报讯（记者王卡拉）"不孕症人数逐年升高，生育障碍性疾病种类呈现多样性，诱发生殖障碍性疾 病的因素日趋复杂，传统辅助生育治疗已经不能满足不断增加的需求。" "在辅助生殖领域，精准医学的应用，可以帮助医生更好地为患者制定精准有效的治疗方案，提高生育 成功率。"北京家恩德运医院翟志瑾博士指出，辅助生殖治疗患者的个体差异大，治疗节点多，其治疗 及发展与精准医学密不可分，各环节的精准把控是确保助孕结局的关键要素。 6月3日，在"精准医学视角下辅助生殖技术-IVF临床个性化及相关治疗与卵母细胞体外培养成熟研讨 会"上，北京家恩德运医院院长刘家恩博士指出上述现状并表示，随着精准医疗概念的提出，辅助生殖 技术领域的精准化治疗越来越得到生育专家的重视。现代精准医学理念促进了辅助生殖领域推进精准化 治疗，提高了生育成功率。 "通过整合先进技术、动态监测和个体化诊疗方案，我们正在推动辅助生殖技术从传统经验医学向 ...

IDEAYA Biosciences (IDYA) 2025 Conference June 04, 2025 08:10 AM ET Speaker0 Hi everyone. My name is Maury Raycroft and one of the biotech analysts at Jefferies. So it's a great pleasure that I'd like to welcome the IDEA team. We've got Yajiro Hata, CEO, and Josh Blaharski, the CFO. Thanks so much for joining us today. Speaker1 Great. Thanks so much Maury and thank you to Jeffries for the opportunity to participate this year and Josh and I will be talking today. Thanks again. Speaker0 And we're going do fir ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 ▍肥胖药物治疗需科学规范 肥胖已发展为全球突出的公共健康难题，我国超重及肥胖人数已逾6亿。《减肥药物临床实践医药专家共识》围绕药物疗效、安全性及个体化方 案，首次全面梳理并发布24条专业建议，为临床从药物选择到特殊人群管理提供全方位路径。共识指出，药物治疗应基于生活方式调整，构 建"生活干预+药物"为支撑的综合管理体系。 ▍药物治疗与生活方式干预的协同 1. 科学设定药物减重目标 疗效显著：临床证据显示，规范应用减重药物可带来5%-15%的体重下降，GLP-1类药物（如司美格鲁肽、替尔泊肽）在III期研究中帮助肥胖 患者减重15%-20.9%，同时改善血糖、血脂等多项代谢指标（见推荐1、13）。 减重目标全面升级：不仅关注体重下降数值，更强调长期体重维持、并发症缓解（如心血管事件风险降低20%）及生活质量提升，部分药物 （如替尔泊肽）更被证实可逆转非酒精性脂肪性肝炎（见推荐4、10）。 2. 生活方式干预为减重基石： 共识指出，饮食调整（如低碳水饮食） ...

Core Viewpoint - Kura Oncology and Kyowa Kirin have announced the acceptance of a New Drug Application (NDA) for ziftomenib by the FDA, targeting adult patients with relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation, with a PDUFA target action date set for November 30, 2025 [1][2] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline of small molecule drug candidates [7] - Kyowa Kirin is a Japan-based global specialty pharmaceutical company with over 70 years of experience in drug discovery and biotechnology innovation [8] Drug Development - Ziftomenib is an investigational menin inhibitor that has received Breakthrough Therapy Designation (BTD), Fast Track, and Orphan Drug Designations from the FDA for the treatment of adult patients with R/R AML with an NPM1 mutation [3][6] - The NDA is based on positive results from the Phase 2 KOMET-001 trial, which achieved its primary endpoint of complete remission and demonstrated a favorable safety profile with limited myelosuppression [2][3] Clinical Trial Insights - The KOMET-001 trial is designed to assess the clinical activity, safety, and tolerability of ziftomenib, and full data analyses will be presented at the 2025 ASCO Annual Meeting and the 2025 EHA Congress [3][4] - Adult patients with R/R NPM1-m AML have a poor prognosis, with only 30% overall survival at 12 months in the relapsed setting, highlighting the urgent need for innovative treatment options [4][5] Market Potential - There are currently no FDA-approved therapies specifically targeting NPM1-m AML, indicating a significant market opportunity for ziftomenib if approved [5][6]

针对小患者特殊情况，庞继景教授团队引入一项基于神经可塑性的新型疗法——视知觉学习训练。通过 电脑生成的Gabor视标，对大脑视觉皮层进行定向激活。经过4个月的系统训练，小患者右眼视力从0.7 提升至0.9，并稳定维持。患儿的屈光度进展也得到了有效控制。 自创立以来，何氏眼科一直坚守"科技报国 科技惠民"的初心，以科技创新为引领，为百姓健康谋福 祉。近年来，何氏眼科与辽宁何氏医学院、何氏眼产业集团等战略合作伙伴协同发展，围绕"健康中 国"战略方向和全球眼健康总体方向，以构建"智慧光明城"为战略目标，发挥独特的眼健康全产业链生 态平台优势，聚焦基因治疗、干细胞再生医学、智能眼科设备数据应用三大领域，开展眼科领域的前沿 技术研究，促进眼科前沿技术与医疗健康数据的深度融合与智能应用，为公司高质量发展注入新的活 力。 庞继景教授表示，该技术核心在于利用大脑的"可塑性"，通过反复训练，大脑可以重新建立更高效的视 觉处理路径。这种训练不仅能改善视力，还能为未来的基因治疗打下基础，通过提前"预热"大脑的视觉 通路，一旦基因干预成功，患者的视功能恢复将更加全面。 （编辑 张昕） 目前，何氏眼科已将视知觉学习训练逐步应用于难治性 ...

近年来， 类器官技术 作为生命科学领域的颠覆性突破，正迅速从实验室走向临床转化。通过体外三维培养 构建的类器官，不仅高度模拟真实器官的结构与功能，更为疾病机制研究、药物筛选及个性化治疗提供了 全新工具。在精准医学浪潮下，类器官与自动化技术的深度融合，正加速科研成果向实际应用的跨越。 2025年5月14日下午14:00-15:30 ，由 Opentrons 联合 ISCO （ 干细胞与类器官创新计划组织 ） 举办 的 "AI自动化解决方案加速类器官研究与药物开发"线上研讨会 即将上线！本次活动汇聚高校学者、技术专 家及产业先锋，聚焦类器官技术的学术突破与自动化解决方案，助力科研与医疗实践的高效衔接。 会议日程 .. 报告主题:类器官在精准医学中应用 14:00-14:30 ● 高正良 上海大学医学院研究员 嘉宾阵容 林鑫华 粤港澳大湾区精准医学研究院执行院长 报告主题: Opentrons类器官自动化解决方案 14:30-15:00 ♀ 林德麟 Opentrons 大陆地区应用技术支持工程师 15:00-15:30 ○ 报告主题: 类器官在脑发育和疾病中的应用 林鑫华 粤港澳大湾区精准医学研究院 执行院长 ● ...

"第十四届胸痛中心大会"近日在江苏苏州召开。大会公布，我国胸痛中心建设成果显著，截至目 前，全国已有近六千家医疗机构启动胸痛中心建设，其中3187家医院通过认证。与会专家围绕胸痛中心 建设成果、面临的挑战及未来发展方向等议题展开交流探讨，旨在进一步完善我国胸痛救治体系，提升 心血管疾病尤其是急性胸痛相关疾病的救治水平，为保障人民群众生命健康筑牢坚固防线。 以AI技术赋能胸痛中心建设 "人工智能在胸痛中心建设及心血管诊疗全流程中正发挥不可替代作用。"武汉大学人民医院（省人 民医院）党委书记黄恺认为，其核心优势体现在：一是精准识别共性问题，通过学习海量医学影像与心 电图数据，AI能够发现医生个体在处理少数病例时易忽略的细微指标，从而提升诊断准确性；二是整 合多模态数据，AI可将病史、视网膜扫描等多源数据进行复杂整合，为疾病预后判断提供更全面依 据；三是推动精准医学发展，结合基因信息为个性化治疗方案制定提供支持。 此外，黄恺还提到，在基层医疗场景中，人工智能的应用价值尤为突出，它能有效弥补基层医生专 业训练背景差异带来的能力差距，为慢病管理提供标准化、高水平的辅助支持。 努力织密基层胸痛救治网络 加快整合区域优质医 ...